Silo Pharma Inc. (NASDAQ: SILO) Granted US Patent For SPC-15 to Prevent and Treat Stress-Induced Disorders
SILO issued US Patent by USPTO titled “Pharmacological Prophylactics Against Stress-Induced Affective Disorders In Females” Claims allowed by patent protect use of SPC-15 for treating stress-induced affective disorders, including anxiety and PTSD Other therapeutics in company pipeline include SPU-16 to treat multiple sclerosis, SPU-21 to treat rheumatoid arthritis, SPC-14 to treat Alzheimer’s disease Therapeutics developed by SILO may qualify for FDA’s streamlined 505(b)(2) regulatory drug approval pathway Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, was recently issued US Patent 11,491,120 by the US Patent and Trademark Office (“USPTO”) (https://nnw.fm/HmROW). The…